



MCan WHITEPAPER

CONTENT

Disclaimer

Message to Investors

Executive Summary

MCan Background

Successful IPO'S taken live

EIMCR

EIMCR & Cultivation

Project Scope

Current Market

Customers/Users

Market Overview

Medicinal Properties of Cannabis

Eight Major Cannabinoids

Current Research

Pricing of Cannabis

Future of Cannabis

Process to Extract Cannabis Oil

MCan - Products from Cannabis

Financial Projections

Investments

ICO

Coin Technology and Blockchain Uses

ICO Key Dates

Coin Distribution

Proceeds Allocation

Fund Allocation

How to buy MCan Coin

MCan refer a friend promotion

Roadmap

Team behind the vision

Appendix

Disclaimer

- a. The purpose of this White Paper is to present Vichy International Company and MCan Coin to potential Coin holders in connection with the proposed Coin sale.
- b. The information set forth below may not be exhaustive and does not imply any elements of a contractual relationship.
- c. Its sole purpose is to provide relevant and reasonable information to potential Coin holders in order for them to determine whether to undertake a thorough analysis of the company with the intent of purchasing MCan Coins.
- d. Nothing in this White Paper shall be deemed to constitute a prospectus of any sort or a solicitation for investment, nor does it in any way pertain to an offer or a solicitation of an offer to buy any securities in any jurisdiction.
- e. This document is not composed in accordance with and is not subject to, laws or regulations of any jurisdiction, which are designed to protect investors.
- f. MCan Coin is a utility Coin. This product is not a digital currency, security, commodity, or any other kind of financial instrument. This has not been registered under the Securities Act, the securities laws of any state of the United States, or the securities laws of any other country, including the securities laws of any jurisdiction in which a potential Coin holder is a resident.
- g. MCan Coin is not intended for sale or use in any jurisdiction where these are prohibited.
- h. MCan Coin confers no other rights in any form, including but not limited to any ownership, distribution (including but not limited to profit), redemption, liquidation, proprietary (including all forms of intellectual property), or other financial or legal rights, other than those specifically described in the White Paper.

i. All statements contained in this Whitepaper, statements made in press releases or in any place accessible by the public and oral statements that may be made by MCan Live Platform or their respective directors, executive officers, employees or team's representatives acting on behalf of MCan Platform (as the case may be), that are not statements of historical fact, constitute "forward-looking statements". Some of these statements can be identified by forward-looking terms such as "aim", "target", "anticipate", "believe", "could", "estimate", "expect", "if", "intend", "may", "plan", "possible", "probable", "project", "should", "would", "will" or other similar terms. However, these terms are not the exclusive means of identifying forward-looking statements. All statements regarding MCan Platform's financial position, business strategies, plans and prospects and the future prospects of the industry which MCan Platform is in are forward-looking statements. These forward-looking statements, including but not limited to statements as to MCan Platform's revenue and profitability, prospects, future plans, other expected industry trends and other matters discussed in this Whitepaper regarding MCan Platform are matters that are not historical facts, but only predictions.

j. White Paper can be modified to provide more detailed information. This English language White Paper is the primary official source of information about the MCan Coin.

Message to Investors

Dear Investor(s),

As Chairman and co-founder of numerous organizations, I fully understand the expectations various investors. Nowadays, investor(s) are looking for companies with stability, growth, high profitability, state of the art technology and ideally one that is operating in a new booming industry. Medical Cannabis industry (MCan) fulfills all these categories and now combined with the cryptocurrency revolution which will enhance the company.

Our Genetically Modified Medical Cannabis has properties to be extracted several times higher than any other ordinary Cannabis for the Medical purpose(s). This new genetically modified species can revolutionize medical cannabis and ultimately find a solution(s) for the treatment of most un-diagnostic diseases.

European Institute of Medical Cannabis Research (EIMCR) wholly owned subsidiary of Vichy International Limited is geared up for this challenge. Our research journey since 2009 will empower patients with medicines that will enhance their lives and allow them to live a healthy life. The research journey has been the best parts of our lives, and we are thrilled to be revolutionizing pharmaceutical industry using Cannabis.

We believe that cannabis has the potential to treat Chronic Cancer, Multiple Sclerosis, HIV/AIDS, Post-Traumatic Stress Disorder and many diseases that are chronic. We firmly believe that more medicine for other uncommon diseases can be found in our species if we do more advanced laboratory research.

Our team has a proven record of accomplishment by listing companies on NASDAQ, London Stock Exchanges, etc. The current revenue of Vichy International Limited is \$60 million, and we believe that the company will grow to around \$500 million in the next seven years. We can share revenue & dividend to our Coin holders. The Coin holders in the future will be the shareholders in Vichy International Limited when the company lists on NASDAQ or the London Stock Exchange.

Regards

Chandra Sekar

Chairman & Founder

Vichy International Limited

EXECUTIVE SUMMARY:

Cannabis production has evolved to be the fastest growing industry in today's world. Possessing powerful properties to cure various chronic diseases, the medical Cannabis industry attributes to 52% of the total Cannabis market. This industry will grow to a \$140 billion industry by 2027.

The research has proven futile to find a proper cure for chronic diseases. There is no other plant that contains medically active properties as Cannabis. The problem arises due to the fact that there are legal restrictions that belittle the growth of the Cannabis-based therapeutics. The medical Cannabis can be taken in many forms - from inhalation to edibles and tinctures, cannabinoid-rich-lotions, serums, oils, pills, and capsules. Testing and quality controls are an important aspect of the research of medical Cannabis.

To prove beneficial, the company has begun researching in EIMCR and plans to expand their scope of research. The focus is on the Genetic development and Nurturing through state-of-the-art technologies. The institute also works on identification and registration of new Cannabis species that might be discovered during the research.

The objective is to apply for licenses to produce medical Cannabis and use the portion of funds for further support of EIMCR. A jaw-dropping fact is that the Medical Cannabis industry is estimated to reach \$20-35 billion by 2020.

the company will conduct an ICO. Through these virtual currency Coins that are known as "Medical Cannabis" (MCan), the company will raise funds for the development of MCan as a project.

MCan Background

The EIMCR leads the way for genetic research and development of Cannabis plant. the company will operate a cultivation facility and eventually set up a manufacturer of Medical Cannabis. The Cannabis plant is medically re-engineered to aid in the medical upliftment. The pharmaceutical preparations are tested and the outcome is vapor pens, Capsules, Injections and Medical sprays.

We can extract 14 times more of THC and CBD than regular strains. To establish the aforementioned idea, MCan came into existence. The Coins will be listed on many prominent exchanges which will enable investors to trade with ease. The unique feature of this Coin is Gas Refill. Through the MCan Coins, the company aims to cure chronic diseases.

MISSION

To eradicate diseases and create well-being for mankind. the company plans to establish and expand throughout the world. The stakeholders will have a mutual growth while contributing to the betterment of humanity.


SUCCESSFUL IPO'S TAKEN LIVE

There have been highly successful IPO'S such as Trevira Gmbh a German Company, Polysindo Eka Perkasa which is currently known as Asia Pacific Fibre.

Trevira Gmbh is a german company that manufactures polyester fibres and filament yarns for home and household textiles, apparel and more. The company offers special fiber types for ring yarn, woolen yarn, filament yarn and more associated products. It also offers low pill fibers, flame retardant fibers etc.

Asia Pacific fiber is an integrated global polyester player. Experts in vertical integration, professional management and consistent quality in manufacturing, the company has evolved into the most progressive and flexible polyester producer.

EIMCR



Vichy International Ltd (promoter of the company) was established through its wholly owned subsidiary European Institute of Medical Cannabis Research (EIMCR) in 2009. Vichy International Limited BVI (company number 1463187) is incorporated in the British Virgin Islands as a BVI business company on the 6th day of February 2008. The purpose is to coordinate rigorous scientific studies to assess the safety of Medical Cannabis. The Instituteworks on identification and registration of new Cannabis species that will likely be discovered during the research.

The institute consists of an excellent team of scientists, unique Cannabis species, advanced technologies and a robust scientific community. EIMCR aims to expand the knowledge of Cannabis to reach high standards of research methods.

EIMCR AND CULTIVATION

The Medical marijuana market was worth \$8.28 billion in 2017 and is expected to grow to \$140 billion by 2027. Medical Cannabis is used in the treatment of oncological, neurological and autoimmune conditions. The Medical Cannabis can also be prescribed in the following terms:


- To relieve symptoms of Multiple Sclerosis and muscle spasms.
- To relieve nausea caused by treatment with chemotherapy and Radiotherapy.
- Treatment for Refractory Epilepsy
- To stimulate appetite in patients with HIV.

The EIMCR wants to conduct a study to understand and determine the value and safety of Cannabis-based medicines in the treatment. The EIMCR would like to research the possibilities of Cannabis reducing the reflex in multiple sclerosis and Alzheimer's disease.

The research will help gain new theoretical knowledge and translate experiments to clinical practices. EIMCR aims to present results at national and international meetings of medical societies that use Medical Cannabis.

Operational Plan - Investment of funds (Redesign Required)

Figure i: Overview of stages of production



Creating cost-efficient cultivation is a must for businesses to thrive. The requirements are as follows:

- 20 hectares of farmland and 40,000 square meters of indoor space.
- A minimum of 150 laborers.
- Competent staff with appropriate skills.
- Personnel Training
- Personal Hygiene
- Security
- Buildings and facilities
- Production and maintenance
- Seeds and labeling material

The cultivation happens in three methods - Outdoor, greenhouse and indoor.

The harvest season for outdoor cultivators is once a year in the fall.

The indoor cultivators can produce year-round generating between 4 and 6 harvests per year.

Greenhouse cultivators are a combination of exploiting natural light and leveraging infrastructure and technology. The harvest can be between 1-4 times a year.

the company will be well equipped with greenhouses that can run year-round. Good cultivation practices will be applied in the cultivation of Cannabis.

Harvesting



The conditions maintained will be wet soil or extremely high air humidity.

- Ventilation is essential in the production, transport, and storage.

Primary Processing




Primary processing includes washing, cutting before drying, decontamination, freezing, distillation, drying, etc.

Drying

A uniform drying speed of the crops and the prevention of mold growth by appropriate measures will be assured.



GREENHOUSE AND CULTIVATION DESIGN



The institute plans on building 2000 greenhouses of 3600 sq ft each during the first year.

These combine the latest technology in HVAC, light deprivation, environmental controls, irrigation, insect exclusion, benching systems and hybrid techniques.

REQUIREMENTS:

- The biggest advantage is the abundance of natural light coming into the greenhouse.
- CO2 is essential for maximizing the quality and production of Cannabis.
- The Cannabis needs long daylight during the vegetative period and a good blackout for the flowering production.
- Heating and cooling systems are important.

PROJECT SCOPE

the company intends to infiltrate into the Medical Cannabis Cultivation market and set up European Institute of Medical Cannabis Research (EIMCR)

CURRENT MARKET

A new market research study published by Ameri Research estimates the global Cannabis market to be worth \$63.5 billion by 2024. Previously valued at \$14.3 billion, the global market is expected to grow at an annual growth rate of 21.1 % between 2017 and 2024.



The forthcoming years will witness legalization and increase in the usage of Medical Cannabis. In 2017, the Canadian government introduced a bill to legalize recreational Cannabis. Germany passed a law to legalize Cannabis for medical purposes.

Customers/Users

Main customers are dispensaries (medical users) and manufacturers of edible products and medical products.

MARKET OVERVIEW

Pain management will remain a priority in the Medical Cannabis industry followed by cancer. For the past 4000 years, Bhang has been actively used in the traditions and customs of the Indian Subcontinent. Bhang is an edible preparation of Cannabis in food and drink. Cannabis edibles are one of the fastest growing categories in the legal weed market.




MEDICINAL PROPERTIES OF Cannabis


Cannabis contains over 480 compounds, 80 of which are only found in Cannabis. These 80 properties are known as cannabinoids. These interact with body receptors inducing effects to nervous system and brain.

Cannabis is a natural pain reliever. The safe ingestion of Cannabis can be a healthier option than medicines.

8 MAJOR CANNABINOIDS IN Cannabis




THC




THC stands for delta-9-tetrahydrocannabinol and it is the most commonly recognized and abundantly found in Cannabis. It is the reason for the psychoactive effect when consuming Cannabis. This is due to the release of dopamine creating a sense of euphoria. In addition, THC also helps in pain management and inflammation.

CBD




Cannabidiol is second most abundant cannabinoid in Cannabis. This has serious implications in medicine and is sought after by medical users. CBD helps in chronic pain, inflammation, migraines, arthritis, spasms, schizophrenia and migraines

CBN




Cannabinol or CBN for short is an analgesic that is formed by the breakdown of THC by oxidation. It is mildly psychoactive, however, it is found only in mild quantities in fresh Cannabis plants.

CBG



CBG is Cannabigerol is an active compound that has antibacterial effects, prevalent in many Cannabis strains. CBG has found to cause relaxation due to uptake with GABA (gamma-Amino-butyric acid) that will have larger implications.

THCV



THCV is Tetrahydrocannabivarin is cannabinoid moderating the intensity of the psychoactive effects of THC. Current research says that THCV can be used to treat metabolic disorders.

There are other Compounds in Cannabis like Cannabichromene (CBC), THCA (an acid form of THC) which acts as a pain reliever. In addition, CBDA helps in anti-nausea effects during the treatment of breast cancer.

CURRENT RESEARCH

It is found that Cannabis has many uses in pain management as well as treating other diseases.

Some of the diseases are:

- HIV/AIDS
- Multiple Sclerosis (MS)
- Epilepsy

PRICING OF Cannabis


The Cannabis industry witnessed high fluctuations through the year 2016. The price stabilized by the end of 2016 at \$1,562. Jonathan Rubin of Cannabis Benchmarks states that the cost of Cannabis is similar to commodities that correlate with the harvest schedule.

FUTURE OF CANNABIS

The legal sales of Cannabis are expected to reach to \$140 billion industry by 2027.

- The current market at \$8.28 Billion is expected to increase by 19% from 2018-2024.
- The increase in competition will allow smaller companies to collaborate with larger companies.
- The increase in investment will lead to the entry of national players.

(Redesign Required)



PROCESS TO EXTRACT Cannabis OIL (Redesign Required)

Solvent extraction



Content for above :

Mixing - Add cannabis to ethanol solution Agitate Mixture

Filtration - This can done using filter paper

Evaporation - Evaporate Solvent in boiling water bath under steam of nitrogen bath

Carrier Oil extraction(Redesign Required)




This is content for above pic

Mixing - Add cannabis to ethanol solution Agitate Mixture

Filtration - This can done using filter paper

Evaporation - Evaporate Solvent in boiling water bath under steam of nitrogen bath

Super or Subcritical Carbon Dioxide Extraction (Redesign Required)



Light Hydrocarbon Extraction (Redesign Required)

Compound Extraction using Super-critical CO₂


Liquid CO₂ storage tank → Compressor → Heating → Extactor -->Extact → Condensator

MCAN PRODUCTS FROM Cannabis

MCAN intends to manufacture consumable products using Cannabis.

1. Vapor Pens

The highest quality legal Cannabinoid extracts with pharmaceutical grade coconut oil (refined for inhalation) is used for the production of the gold blend formula.



2. Capsule and Pills



3. Medical Sprays



4. the company Teas




By the end of 2018, the Cannabis tea named “SIP BY SIP” will be launched to provide easy and fast relief for the users. The tea will consist 5mg CBD and 0.5mg THC per serving.

5. ChewCann



The THC infused gum will provide pain relief to patients under chemotherapy and to those suffering from AIDS. The gum will also help in the treatment of pain associated with MS.

FINANCIAL PROJECTIONS (Use image from Website)



Vichy International Ltd (VIL), the promoter of the company is in the third year of operation. Apart from listing the Coin in cryptocurrency exchanges, they are planning to list the company through IPO (Initial Public Offering) on an international stock exchange such as - London stock exchange (LSE) OR Frankfurt stock exchange (DAX) or Oslo stock exchange (OSE) in Norway.

The company is forecasting the market capitalization to be around €500 million. The calculation is derived from the company's EBITDA and Net Income (NI)

The figures in the third operating year will be:

- EBITDA in year 3 - €100M
- Net Income (Profit after Tax) - €52.5 Million

The company will go public with the calculations based on the following:

- $EBITDA \times 5 = €100 \text{ million} \times 5 = €500.0 \text{ Million}$
- $Net \text{ Income (NI) with P/E 10 times} = €52.5 \text{ million} \times 10 = €525.50 \text{ million}$

BENEFITS FOR Coin HOLDERS

- The PRE-ICO Coin buyer gets 30% discount on the Coin price.
- The PRE-ICO Coin holder gets a share of the company when its going public.
- For each 1000 MCan Coin bought during the PRE-ICO period, the company will allocate 1 free listed shares of Vichy International Ltd.
- Subject to the movement of the MCan Coin price The Coin holder will benefit from the capital appreciation of MCan Coin,
- Subject to the movement of the shares price of the Company, the shareholder will benefit the share appreciation of the Company.

INVESTMENTS

The funds allocated include infrastructure development, cultivation, manufacture, marketing expenses, compliance and so on.

(Use image from Website)

INITIAL COIN OFFERING - MCan Coins

During the initial coin offering (ICO), the company will issue virtual currency Coins called Medical Cannabis (MCan) on the blockchain. the company offers a platform for all types of investors contrary to the traditional venture funding that attracts only the elite class. The ICO invites participants from different regions and also incentivize them to promote the company products via affiliate commissions. Coins provide liquidity as they can be traded on various exchanges post-ICO.

PRE-ICO

Before the full ICO, 5% of ICO Coins will be issued to finalize the initial version of Medical Cannabis (MCan). The PRE-ICO will be used to determine the hard cap for ICO. MCan Coins will be priced at 0.1 Euro per Coin.

ICO

The Coin contract will be published in June 2018 and the link will be published on the Coin Sale website.

Coins will be distributed within 7 days of the closing date by providing an address from a compliant wallet.

COIN

The Coin holders can use the MCan Coin to pay for services and products of the company at a discount rate.

Referral commissions will be distributed to holders of Medical Cannabis (MCan) Coins.

Medical Cannabis Coins are not Proof-of-Asset Coins and are not a security under any circumstances. There is no promise of profit or any future value, and the Coins are solely used as a right of access and use of platform services. Medical Cannabis Coins do not constitute a currency equivalent as they are not issued by any government or central issuer, nor do they represent any relationship or rights to the ownership of the protocol.

COIN TECHNOLOGY

The distribution of a new currency is witnessed through an existing transaction ledger. MCan coin was developed with the motive of providing a fair trading opportunity and garner financial security to create a change in the world. MCan coin offers a different initial currency distribution and aims for in-depth community engagement.

Some of the advantages of the coin are:

- **Escalating utilities**

MCan coin has been carefully designed to possess the best features and configuration parameters for maximum utility. The following functionalities of MCan coin maximize benefits.

- Fast: Rapid transactions and confirmations with 2.5 minute block times
- Cheap: Low spending with less fees
- Scalable: Support and fast blocks provide ample transaction bandwidth
- Future-proof: Lightning network support provides instant transactions and future scalability

- **Full release**

The coin will be released to all participants simultaneously. This resolves the issue of biased experience.

- **Protection**

To prevent fraudulent activities, MCan coin generates transaction signatures. In addition, the coin addresses a different Base58 prefix byte, so that the addresses start with the product name. This prevents user confusion. While the transaction signature changes mean, the network will not validate any transaction sent on the incorrect network, the differing prefix byte and (associated UI validation) will prevent a user trying to create such a transaction.

- **Transparent maintenance of funds:**

MCan coin uses a special block reward defined in the consensus parameters ensuring that the exact maintenance fund amount is rewarded to a vanity address publically visible and hard coded into the source.

What do Investors gain?

Successfully modifying and re-engineering the cannabis plant, MCan has elevated the purchase methods. The MCan coins can be utilized to buy MCan products. The growth of coin holders/investors will be witnessed while the coin supply remains the same. When the investor buys MCan products, they receive discounts and shares.

- The Company offers Revenue Sharing to MCan's coin Holders on a Monthly Basis.
- The Company offers Dividend to MCan Coin Holders on a quarterly basis.
- The Company generously provides 1 free listed share for participants who hold 1000 MCan Coins **bought during Pre-ICO Period** once the Company is listed on NASDAQ or London Stock Exchange.
- Referral commissions of 5% will be distributed via smart contract to holders of Medical Cannabis (MCan) Coins.
- Referral commissions of 5% will be distributed via smart contract to holders of Medical Cannabis (MCan) coins

ICO KEY DATES

Pre ICO:

16th of June 2018 (00:00 GMT) – 27th of July 2018 (23:59 GMT)

ICO

31st of Aug 2018 (00:00 GMT) – 30th of Sept 2018 (23:59 GMT)

Purchase:	1 MCan Coin sold at 0.1 Euro
Coins Available for Sale:	2,750,000,000 MCan (Two Billion & Seven Hundred and Fifty Million)
Min Cap in Coins:	25,00,00,000 MCan (Two Hundred and Fifty Million)


Coin Price:	€0.1
Ticker Symbol:	MCan
Minimum Purchase Per Person:	€15 (=150 MCan)
Total number of Coins	5,000,000,000 MCan
Maximum Purchase Per Subscription:	100,000,000 MCan
Pre-Sale:	250,000,000 MCan

Fundraising Goal:	€500,000,000
Main Sale:	2,750,000,000 MCan
Sale Bonus:	30% During Pre-ICO (500,000,000 MCan available)
Accepted Fiat Currencies:	EUR (€), USD (US\$), GBP (£), YEN (¥), CHF, Indonesian RP, Renmimbi
Accepted Cryptocurrencies:	BTC, ETH, XRP, BCH,
Accepted Nationalities:	Every Nationality, except United States of America, residents of a country where American embargoes and sanctions are in force, namely Iran, North Korea, Syria, Sudan, or Cuba. More information in the Terms of Coin Sale

When the coin distribution ends officially, the sale and purchase agreement on the MCan Coins entered into between the Coin subscribers and the Coin distributor will become legally valid and binding. After this, no additional Coins will be distributed. There will be no further Coins created after the hard cap is reached and the total amount of 5,000,000,000 MCan will not be exceeded.

COIN DISTRIBUTION

The majority of the Coins will be offered during the pre-sale and main sale. The remaining Coins will be distributed among advisors, the team, and bounties. The following graphic shows the planned distribution of the Coins.




(Redesign) Details on the wesite

c

Amount of MCAN your referral has bought	Your Bonus MCAN Credited to your Wallet
150	8
1,000	50
5,000	250

25,000	1,250
100,000	5,000
1,000,000	50,000
10,000,000	500,000
100,000,000	5,000,000

FUND ALLOCATION(Redesign)(Use Website Chart)



HOW TO BUY MCan Coins

Users can buy MCan Coins with Cryptocurrencies or Fiat Currencies.

Option 1 : With Cryptocurrencies

The Users can choose to send ETH, BTC, XRP or BCH to purchase MCan.

MCan will present the user's personal address to send the Coins. After the coin is sent to the wallet, the users can see the number of Coins in the balance. There will be a confirmation email.

The User has to enter the address of ERC-20 compatible wallet to get Coins distributed within 7 days of the Coin sale.

Option 2: With Fiat Currencies

Users can choose to buy Coins using wire transfers to a designated bank account. This transaction of money from the bank account can be made from any part of the world.

When wiring of money is carried out the bank account details with personal reference code will be presented. We at MCan ensure the highest levels of security in the transactional process.

After the deposit has been confirmed and MCan has validated the payment, the user will see the corresponding number of Coins in the balance. The confirmation email will be sent in both processes.

To receive MCan Coins within seven days of the Coin sale, the user has to enter the address of the wallet in the Coin balance screen.

MCan REFER A FRIEND PROGRAMME

The Users are rewarded when they refer potential investors. After signing up with our platform, users will be presented with an exclusive dashboard, where he can purchase his MCan coins in exchange for BTC, BCH, ETH, XRP or wire transfer.

For every sign-up, the system generates a personal affiliate link that will be displayed in the Coin sale area. By sharing links through email, social media or common mobile messengers, the link will lead to the investor dashboard of the Coin.

The affiliate software tracks every referred user and would assign this user to the referrer. In addition, users can monitor the status of each referral in real time.

COMMISSION RULES

A 5% bonus of the Coin amount that the referral bought, will be credited to the user's account.

The referral has to follow the user's personal link, registering for the company website and verifying the email address.

The minimum purchase amount is 150 MCan to qualify for the 5% referral bonus. The maximum purchase amount is 10,000,000 MCan. The referral pool is limited to 30,000,000 MCan. If the referral pool is exceeded there will be no further referral bonus paid. The user will be informed via email, Coin sale webpage and via the client area.

MCan Coins Referral Program Compensation

Amount of MCan your referral has bought	Your Bonus MCan Credited to your Wallet
150	7.5
1000	50
5000	250
25000	1250
100000	5000

1000000	50000
10000000	500000

ROAD MAP

1st Half, 2018

- Project Conceptualization Started
- Corporation with various blockchain specialist, advisors to form strategic alliance
- Form Strategic Alliance with other Medical Cannabis Research and Cultivation companies

2nd Half, 2018

- ICO - Pre-Sale & Institutional Sale
- Pre- ICO 10% & ICO 50% of the coins will be distributed to expand EIMCR
- Form strategic alliance with R&D departments in Universities in the area
- Finalise discussions with Governmental figures

1st Half, 2019

- Strategic Alliance with companies to produce MCan Products
- Establishment of pharmaceutical manufacturing facilities
- Production of MCan cultivation Begins

2nd Half, 2019

- Adding more and the very best Consultants, Doctors and Scientists.
- Medical Cannabis harvest
- All Production of MCan Products Begins

2020

- Aggressive expansion to 13 new countries
- Expansion to new verticals, concrete plans set and teams ready to expand to 13 countries in 2 years.

2021

- IPO (Initial Public Offering in major Global Exchanges)
- NASDAQ, London Stock Exchange (LSE).
- Further expansion & Global dominance
- Aggressive marketing in current markets to 8 more new countries in 2 years.
- Expansion of Manufacturing Facilities in few countries.
- Blockchain era continues

TEAM BEHIND THE VISION




Ø Co-Founder MCan

Ø Project Management (41 years) Project Supervision & Commissioning.

Ø Budgeting Tender adjudication & contract award management in Materials, costs, quality and time management.

Chairman & Founder of

1. Barmag Machinery (Luxembourg) Ltd - T/O 110 M USD
2. Vichy International Ltd - T/O 65 M USD



Ø Co-Founder MCan

Ø Is an Inventor and Entrepreneur, well qualified with an Honours degree in Applied Chemistry and a proven experience in innovation and product development.

Ø Over 35 years' experience

Ø Qualified in CeMap London school finance

Ø Invented Sensidry Diapers that sends text messages when there's a need in care homes. Also, Babyweecare diapers that talk and send text messages when there's a need for changing.


Ø Invented Bluetooth Hands-free Cassette Car Kit.

Ø COO Vichy International Ltd

Ø CEO Phoenix Global Group Ltd



- Ø Dealing with a large group of investors in UK and Israel
- Ø Excellent contacts with major corporations and their management in locally based groups to statewide government officials
- Ø Chief financial officer for Phoenix Global Group
- Ø Total 39 years experience




Agnieszka Wiczorek

Blockchain Developer

- Ø Expert in computer networking, cryptography, algorithms and data structures.
- Ø Possesses solid understanding of blockchain technology and uses.
- Ø Hones strong back end developer skills and expertise in the field of computer science.

Marta Mróz

Executive Director - Safety, Hygiene and Environment



- Ø Had been in the leadership role in Work Health & Safety
- Ø Has created periodic workplace hygiene and safety audit for leading agricultural companies
- Ø Created a health and safety manuals for many institutions
- Ø Ad-hoc health and safety inspections

Ø Legal advisor on Safety, Hygiene, Health and other environmental compliances.



Ø We have Consultants, Doctors and Scientists with broad experience in the biggest European Health Systems which were/are responsible for Clinical Trial Design and Conduction according to GCP-ICH guidelines, development of in vitro and in vivo diseases models.

Ø We also have access to a world-class team of scientists, unique Cannabis species, advanced technologies and a robust scientific community.